$KYMR

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly $13 billion valuation, upside looks limited ahead of the data, RBC Capital Markets said in a note Wednesday.Kymera's phase IIb KT-621 data in atopic dermatitis are expected by year-end 2026. A placebo-adjusted EASI percentage change from baseline of about 35% and an EASI-75 rate of 35% to 40% would be enough to support the view of KT-621 as an "oral Dupixent," the analysts said.The analysts added that while they think the drug is more likely than not to succeed, Kymera's roughly $13 billion fully diluted market cap already reflects significant expectations.Given the $11 billion value set in AbbVie's acquisition of Apogee Therapeutics following positive phase II atopic-dermatitis data, RBC said Kymera's risk-reward setup appears balanced.The analysts said they would seek a better entry point or further progress before recommending investors add to positions.RBC has a Sector Perform rating and a $112 price target on Kymera Therapeutics.Price: $118.65, Change: $-0.40, Percent Change: -0.34%

Deutsche Bank Initiates Kymera Therapeutics at Hold, With $120 Price Target

Kymera Therapeutics Shares Fall After RBC Downgrade

Kymera Therapeutics (KYMR) shares were down 7.6% in Monday trading after RBC downgraded the stock to sector perform from outperform and raised its price target to $115 from $106 with speculative risk.Intraday trading volume stood at about 533,000 shares against a daily average of over 790,000 shares.Price: $110.31, Change: $-9.04, Percent Change: -7.58%

RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk

Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $124.19, according to analysts polled by FactSet.

Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing

Nello Mainolfi, Director, Chief Executive Officer, on July 07, 2026, sold 50,000 shares in Kymera Therapeutics (KYMR) for $5,950,000. Following the Form 4 filing with the SEC, Mainolfi has control over a total of 666,568 common shares of the company, with 666,568 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1815442/000119312526297817/xslF345X05/ownership.xml

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%.The iShares Biotechnology ETF (IBB) advanced 1.3%.In corporate news, Bio-Techne (TECH) shares jumped 20% after the company agreed to be acquired by Germany's Merck in an all-cash deal with an enterprise value of $11.3 billion.Eli Lilly (LLY) shares rose 1% after the company said its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.Kymera Therapeutics (KYMR) shares jumped 16% after the company said it has completed enrollment in a phase 2b trial of KT-621 in moderate to severe atopic dermatitis ahead of schedule.PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating postoperative pain treatment, the company said. The shares climbed 13%.

Sector Update: Healthcare

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.8%.The iShares Biotechnology ETF (IBB) advanced 1.2%.In corporate news, Kymera Therapeutics (KYMR) shares jumped 14% after the company said it has completed enrollment in its phase 2b Broaden2 trial of KT-621 in moderate to severe atopic dermatitis ahead of schedule.

Update: Kymera Therapeutics Advances KT-621 Development With Phase 2b Enrollment Completion; Shares Rise

(Updates with the latest stock movement in the first paragraph and headline.)Kymera Therapeutics (KYMR) shares were up roughly 17% in Thursday trading after the company said it has completed enrollment in its phase 2b Broaden2 trial of KT-621 in moderate to severe atopic dermatitis ahead of schedule.Enrollment was completed nearly six months earlier than expected, allowing Kymera to bring forward the topline data readout to year-end 2026 from mid-2027, the company said.Kymera plans to initiate phase 3 trials in atopic dermatitis by mid-2027 and noted that its phase 2b Breadth trial of KT-621 in eosinophilic asthma is ongoing, with data expected in late 2027, it added.Price: $116.84, Change: $+16.97, Percent Change: +16.99%

Top Midday Gainers

Kymera Therapeutics (KYMR) has completed enrollment in its phase 2b Broaden2 trial of KT-621 in moderate-to-severe atopic dermatitis ahead of schedule, the company said Thursday.Shares jumped 17% following an increase in intraday trading volume to about 2.7 million from a daily average of about 636,000.WidePoint (WYY) stock surged 14% after the company said it won the Department of Homeland Security's Cellular Wireless Managed Services 3.0 contract.More than 5.4 million shares of the company traded intraday compared with a daily average of about 140,000.Bio-Techne (TECH) signed a definitive agreement to be acquired by Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion, the companies said Thursday.Shares climbed 20% as intraday trading volume catapulted to over 40.7 million from a daily average of about 2.7 million.Price: $116.86, Change: $+16.99, Percent Change: +17.01%

Kymera Therapeutics Insider Sold Shares Worth $45,293,294, According to a Recent SEC Filing

Bruce Booth, Director, on June 17, 2026, sold 478,198 shares in Kymera Therapeutics (KYMR) for $45,293,294. Following the Form 4 filing with the SEC, Booth has control over a total of 4,108,316 common shares of the company, with 4,108,316 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1815442/000145161226000010/xslF345X05/form4-06232026_010608.xml

Kymera Therapeutics Insider Sold Shares Worth $3,299,037, According to a Recent SEC Filing

Bruce Booth, Director, on June 17, 2026, sold 31,798 shares in Kymera Therapeutics (KYMR) for $3,299,037. Following the Form 4 filing with the SEC, Booth has control over a total of 4,076,518 common shares of the company, with 4,076,518 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1815442/000145161226000012/xslF345X05/form4-06232026_010614.xml

Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target

Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $118.27, according to analysts polled by FactSet.

Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises

Kymera Therapeutics (KYMR) shares were down 3% in Thursday trading after it reported a Q1 loss of $0.71 per share, narrowing from a loss of $0.82 a year earlier.Analysts surveyed by FactSet expected a loss of $0.88.Collaboration revenue for the quarter ended March 31 was $34.4 million, up from $22.1 million a year earlier.Analysts polled by FactSet expected $8.3 million.As of March 31, Kymera Therapeutics said it had $1.55 billion in cash, cash equivalents, and investments, which it expects to provide the company with a cash runway into 2029.Price: $79.23, Change: $-2.28, Percent Change: -2.80%